PACIFIC BIOSCIENCES OF CALIFORNIA WKN: A1C3EQ ISIN: US69404D1081 Kürzel: PACB Forum: Aktien Thema: Hauptdiskussion

https://www.grandviewresearch.com/industry-analysis/long-read-sequencing-market

Microsoft I am thrilled to share the work the #MicrosoftGenomics team is doing with @PacBio and @ChildrensMercy ! They will be creating Azure cloud-based solutions and AI technologies to better understand the genetic causes of rare diseases in children. #Healthcare

 In his most recent position as Executive Vice President & Chief Commercial Officer, Mr. Henry had direct responsibility for the development and implementation of all aspects of Illumina’s commercial strategy. Mr. Henry also played leading roles in Illumina’s acquisitions of several life sciences companies and led Illumina’s successful integration of Solexa.

https://www.pacb.com/press_releases/pacific-biosciences-appoints-christian-henry-to-board-of-directors/

👀

https://www.pacb.com/blog/meet-the-new-sequel-iie-system/?platform=hootsuite&utm_campaign=twitter

We have added a Sequel II system from Pacific Biosciences to our Next Generation Sequencing facilities. The new platform widens our possibilities to optimally support partners in answering their toughest research questions in crop innovation.

https://www.keygene.com/news-events/pacific-biosciences-sequel-ii-added-to-our-ngs-facilities/?platform=hootsuite&utm_campaign=twitter

https://mobile.twit.ter.com/AlbertVilella/status/1293251018193539073

Man ey 🙈

https://www.mscience.com.au/view/latest-updates/pacbio-hifi-sequencing-overwhelmingly-best-for-human-genome-sequencing

.

News?

Fleißig 😊

https://www.google.de/amp/s/seekingalpha.com/amp/article/4375906-new-leadership-driving-new-interest-in-pacific-biosciences?espv=1

Von ARK This week, Pacific Biosciences of California (PACB) raised nearly $87 million in a secondary equity offering, causing some excitement and an approximate 23% pop in the stock. With a strong balance sheet, PacBio should be able to improve its flagship Sequel II platform, enrich its clinical footprint, and expand its value proposition for translational research customers. Once upgraded, we believe Sequel II could be superior to category leader Illumina (ILMN) as measured by cost, accuracy, and features. Unlike short-read sequencers, Sequel II uses high-fidelity (HiFi) long-read chemistry. While less expensive and more efficient, short read systems fail to recognize certain types of mutations, importantly structural variants. They also can be biased by upstream chemistry steps and are unable to detect epigenomic changes like DNA methylation without specialized reagents. Though historically more expensive, HiFi long reads can overcome all of these challenges. In the recent precisionFDA challenge, an open competition among sequencing platforms and analysis pipelines, 96% of the winners used PacBio HiFi reads. Compared head-to-head with the same analysis tools, Sequel II had 2.5x fewer errors than Illumina’s NovaSeq and roughly 30x fewer errors than Oxford Nanopore’s PromethION system. In our view, with time Sequel II could have more advantages beyond superior accuracy and comprehensiveness. According to our analysis, given its track record and access to capital, PacBio could optimize Sequel II to sequence whole human genomes for less than $1,000 within the next 24 months. Sequel II also should be able to generate as much data per day as the NovaSeq, perhaps forcing Illumina to lower reagent prices or integrate super-resolution optics into its high-throughput instruments more rapidly than otherwise might be the case.